Neuprozyme Therapeutics ApS: Financial statements 2023
CVR: 40010106
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
Neuprozyme Therapeutics ApS (CVR 40010106) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -1,074 and a net result of DKK -21,211 compared with DKK 436,098 the year before. Equity in the 2023 report amounted to DKK 132,805. The solvency ratio was 83.9%.
- Gross Profit
- DKK -1,074
- Profit/Loss
- DKK -21,211
- Equity
- DKK 132,805
- Total Assets
- DKK 158,305
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -1K | -21K | 133K | - |
| 2022 | - | 576K | 436K | 154K | - |
| 2021 | - | 1M | -289K | -282K | - |
| 2020 | - | -39K | -36K | 7K | 0 |
| 2019 | - | -8K | -8K | 43K | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationAbout Neuprozyme Therapeutics ApS
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.